biotech · Solid Tumors · Pancreatic Cancer · MREO
MEREO BIOPHARMA GROUP
Mereo BioPharma Group plc
MEREO BIOPHARMA GROUP clinical programs — 24 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 4TH FLOOR, ONE, LONDON, USA
- Employees
- 4
- Programs
- 47
- Drugs
- 22
- Patents
- 18
MEREO BIOPHARMA GROUP projects
24 ClinicalTrials.gov programs sponsored by MEREO BIOPHARMA GROUP.
MEREO BIOPHARMA GROUP has 24 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
BCT197
Mereo BioPharma Group plc
Interaction
2 trials -
Demcizumab
Mereo BioPharma Group plc
Locally Advanced or Metastatic Solid Tumors
1 trial -
Demcizumab
Mereo BioPharma Group plc
Non Small Cell Lung Cancer
1 trial -
Demcizumab
Mereo BioPharma Group plc
Primary Peritoneal Carcinoma
1 trial -
Docetaxel
Mereo BioPharma Group plc
Solid Tumors
1 trial -
OMP-131R10
Mereo BioPharma Group plc
Advanced Relapsed Tumors
1 trial -
OMP-18R5
Mereo BioPharma Group plc
Solid Tumors
1 trial -
OMP-21M18
Mereo BioPharma Group plc
Colorectal Cancer
1 trial -
OMP-21M18
Mereo BioPharma Group plc
Solid Tumors
1 trial -
OMP-305B83
Mereo BioPharma Group plc
Metastatic Colorectal Cancer
1 trial -
OMP-305B83
Mereo BioPharma Group plc
Advanced Solid Tumor Malignancies
1 trial -
OMP-305B83
Mereo BioPharma Group plc
Cancer Ovaries
1 trial -
OMP-313M32
Mereo BioPharma Group plc
Locally Advanced Cancer
1 trial -
OMP-336B11
Mereo BioPharma Group plc
Locally Advanced Malignant Neoplasm
1 trial -
OMP-52M51
Mereo BioPharma Group plc
Relapsed or Refractory Lymphoid Malignancies
1 trial -
OMP-52M51
Mereo BioPharma Group plc
Relapsed or Refractory Solid Tumors
1 trial -
OMP-54F28
Mereo BioPharma Group plc
Solid Tumors
1 trial -
OMP-54F28 with Sorafenib
Mereo BioPharma Group plc
Hepatocellular Cancer
1 trial -
OMP-54F28, Nab-Paclitaxel and Gemcitabine
Mereo BioPharma Group plc
Pancreatic Cancer
1 trial -
OMP-54F28, Paclitaxel and Carboplatin
Mereo BioPharma Group plc
Ovarian Cancer
1 trial -
OMP-59R5
Mereo BioPharma Group plc
Solid Tumors
1 trial -
Vantictumab
Mereo BioPharma Group plc
Pancreatic Cancer
1 trial -
Vantictumab combined with paclitaxel
Mereo BioPharma Group plc
Metastatic Breast Cancer
1 trial -
brontictuzumab
Mereo BioPharma Group plc
Metastatic Colorectal Cancer
1 trial
Frequently asked questions
How many clinical projects does MEREO BIOPHARMA GROUP have?
24 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.